Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Target Raised at JPMorgan Chase & Co.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective raised by equities researchers at JPMorgan Chase & Co. from $20.00 to $22.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 55.06% from the company’s current price.

SRPT has been the topic of several other research reports. Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. William Blair raised Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, November 12th. Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. Finally, HC Wainwright restated a “sell” rating and set a $5.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 5th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and six have given a Sell rating to the company. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Hold” and an average target price of $23.80.

Read Our Latest Stock Report on Sarepta Therapeutics

Sarepta Therapeutics Price Performance

NASDAQ:SRPT traded down $0.34 on Thursday, hitting $14.19. The company had a trading volume of 936,446 shares, compared to its average volume of 2,969,910. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -10.35, a PEG ratio of 0.36 and a beta of 0.45. The company has a current ratio of 3.46, a quick ratio of 2.13 and a debt-to-equity ratio of 0.46. The firm has a 50 day moving average of $18.17 and a two-hundred day moving average of $18.42. Sarepta Therapeutics has a 52 week low of $14.22 and a 52 week high of $24.68.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $381.35 million for the quarter, compared to analysts’ expectations of $352.20 million. Sarepta Therapeutics had a negative net margin of 5.86% and a negative return on equity of 0.20%. The company’s revenue was down 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. On average, research analysts anticipate that Sarepta Therapeutics will post 3.15 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in Sarepta Therapeutics by 26.6% during the first quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock worth $46,695,000 after acquiring an additional 450,336 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in Sarepta Therapeutics in the second quarter worth $8,165,000. GSA Capital Partners LLP bought a new stake in Sarepta Therapeutics in the second quarter valued at $1,862,000. Canada Pension Plan Investment Board bought a new stake in Sarepta Therapeutics in the second quarter valued at $1,272,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $927,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.

See Also

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.